Table 3 Clinical characteristics of the high-versus the low-serum creatinine/cystatin C ratio group
High (Cr/CysC ≧ 0.88) | Low (Cr/CysC < 0.88) | P value | |
|---|---|---|---|
Number of patients | 24 | 25 | |
Age, years | 69.0 ± 8.3 | 76.8 ± 4.8 | < 0.001 |
Sex, female, n (%) | 1 (4.2) | 4 (16.0) | 0.35 |
Body mass index, kg/m2 | 23.5 ± 2.3 | 21.1 ± 3.4 | < 0.01 |
Severity | |||
GAP index | 3 [2.5–4] | 3 [3, 4] | 0.06 |
GAP stage (I/II/III), n (%) | 17/ (71)/7(29)/0(0) | 13(52)/12(48)/0(0) | < 0.001 |
Pulmonary function | |||
FVC, % predicted | 82.0 ± 13.5 | 78.9 ± 17.4 | 0.49 |
FEV1, % predicted | 81.2 ± 13.0 | 82.6 ± 16.5 | 0.74 |
DLCO, % predicted | 68.7 ± 15.5 | 66.3 ± 22.2 | 0.65 |
PaO2, mmHg | 92.3 [87.1–101] | 82.0 [74.4–88.7] | < 0.005 |
Physical assessment | |||
Handgrip strength, kg | 35.5 ± 5.7 | 27.4 ± 8.4 | < 0.001 |
Usual gait speed, m/s | 1.17 ± 0.23 | 1.04 ± 0.28 | 0.08 |
6MWT | |||
Distance, m | 441 ± 81 | 392 ± 90 | 0.05 |
Lowest SpO2, % | 90 [86–93] | 88 [82–92] | 0.13 |
ASMI, kg/m2 | 7.25 ± 0.78 | 6.34 ± 0.93 | < 0.001 |
SARC-F | 1.5 [0–2] | 3 [1–5] | < 0.05 |
Patient-reported outcomes | |||
mMRC | 0 [0–1] | 2 [1–3] | < 0.001 |
CAT | 10 [5–17] | 13 [8.5–25] | < 0.05 |
K-BILD | |||
Psychological | 57 [48–64] | 55 [42–63] | 0.22 |
Breathlessness and activities | 50 [42–56] | 46 [32–54] | < 0.01 |
Chest symptoms | 73 [64–79] | 73 [54–85] | 0.20 |
Total | 60 [54–63] | 55 [47–61] | 0.05 |
Blood examination | |||
Creatinine (mg/dL) | 0.90 [0.79–1.08] | 0.77 [0.72–0.97] | 0.06 |
Cystatin C (mg/L) | 0.91 [0.82–1.13] | 1.08 [0.95–1.26] | < 0.01 |
Cr/CysC ratio | 0.94 [0.90–1.05] | 0.77 [0.71–0.80] | < 0.001 |
Comorbidity | |||
Hypertension, n (%) | 14 (58%) | 14(56%) | 0.87 |
Dyslipidemia, n (%) | 10 (42%) | 8 (20%) | 0.48 |
Diabetes mellitus, n (%) | 7 (29%) | 6 (24%) | 0.68 |
Coronary artery disease, n (%) | 4 (17%) | 1(0.4%) | 0.14 |
Chronic kidney disease, n (%) | 2 (0.8%) | 0 (0%) | 0.14 |
Sarcopenia, n (%) | 3 (13%) | 15 (60%) |  < 0.001 |